New Blood Test Predicts Dementia 25 Years Early

A new blood test shows promise in predicting dementia risk in women up to 25 years before symptoms manifest. Research from the University of California San Diego identified a protein biomarker, phosphorylated tau 217 (p-tau217), which is strongly linked to the early pathological processes of Alzheimer's disease. Analysis of blood samples from older women revealed that higher levels of p-tau217 were associated with a significantly increased likelihood of developing mild cognitive impairment and dementia over the following two decades.

This discovery could revolutionize dementia care by allowing for earlier detection and intervention. Identifying individuals at high risk long before cognitive decline impacts daily life may enable the development of strategies to delay or prevent the disease's progression. The p-tau217 blood test offers a less invasive and potentially more accessible method compared to brain imaging or spinal fluid analysis, accelerating research into risk factors and preventative measures.